Research Reveals Impact of Eli Lilly's Weight Loss Drug Rebound:
A study indicates that a year after discontinuing Eli Lilly's weight loss drug Zepbound, participants who had previously taken it for eight months experienced a slow rebound in weight, with half of the lost weight regained.
As a result, Eli Lilly's stock price took a dive at the opening of the U.S. stock market, experiencing an overall drop of 3.8% on that day, hitting a new low of $574.91. Novo Nordisk's st...

November CPI numbers were in line with expectations, which means rates will remain essentially unchanged until mid to late next year.
CPI y/y +% versus 3.1% expected
Prior y/y 3.2%
CPI m/m +0.1% versus 0.0% expected
Prior m/m 0.0%
Markets whipsawed in the wake of the print, with Treasury yields initially falling across the curve before reversing higher. The US 2-year yield is now up 2.3 basis points, though market expectations for rate cuts in 202...